In Vitro Activity of Plazomicin among Carbapenem-resistant Enterobacteriaceae

Sara Essam; Nada Nawar; Mohamed ElBashaar; May Soliman; May Abdelfattah

doi:10.3889/oamjms.2021.7579

Authors

Sara Essam Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Giza, Egypt
Nada N Nawar Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Giza, Egypt
Mohamed ElBashaar Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Giza, Egypt
May Soliman Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Giza, Egypt
May Abdelfattah Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Giza, Egypt

DOI:

https://doi.org/10.3889/oamjms.2021.7579

Keywords:

Carbapenem-resistant Enterobacteriaceae, Plazomicin, Multiplex polymerase chain reaction, Modified carbapenem inhibition method

Abstract

Background: Carbapenem-resistant Enterobacteriaceae (CRE) have been disseminated worldwide and became a global threat. Due to limited therapeutic drugs plazomicin - a new semisynthetic aminoglycoside - have been suggested as an alternative option owing to its stability against aminoglycosides modifying enzymes (AMEs). This study aims to assess the in vitro activity of plazomicin against CRE isolates and to detect different types of carbapenemases among these isolates.

Material and Methods: In this study, 102 CRE isolates were collected from different clinical samples at Cairo University hospitals and the presence of carbapenemases was detected by modified carbapenem inhibition method (mCIM) and multiplex PCR tests. Plazomicin susceptibility testing was done using E test.

Results: The most frequently detected carbapenemase genes were bla_NDM in 75 (73.5%) isolates, followed by bla_OXA-48 in 57 (55.9%) and bla_KPC in 16 (15.5%) isolates. Plazomicin was active against 32 (31.4%) isolates. Among the isolates carrying bla_NDMgene only and those carrying bla_OXA-48 gene only, 21% and 41% were sensitive to plazomicin, respectively. Plazomicin showed the highest sensitivity against CRE isolates compared to the other tested antibiotics.

Conclusion: Plazomicin might be a good option for treatment of infections caused by CRE. In health care settings where bla_NDMgene is prevalent, plazomicin may not be a good therapeutic option for CRE infections.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Harting J. Carbapenem-resistant Enterobacteriaceae infections: A review of epidemiology and treatment options. Univ Louisville J Respir Infect. 2019;3(1):4. DOI: https://doi.org/10.18297/jri/vol3/iss1/4

Temkin E, Adler A, Lerner A, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: Biology, epidemiology, and management. Ann N Y Acad Sci. 2014;1323(1):22-42. https://doi.org/10.1111/nyas.12537 PMid:25195939 DOI: https://doi.org/10.1111/nyas.12537

Centers for Disease Control and Prevention. Facility Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE)- November 2015 Update CRE Toolkit. Atlanta, GA: United States Department of Health and Human Services; 2015.

Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17(10):1791. https://doi.org/10.3201/eid1710.110655 PMid:22000347 DOI: https://doi.org/10.3201/eid1710.110655

Schwaber MJ, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: A potential threat. JAMA. 2008;300(24):2911-3. https://doi.org/10.1001/jama.2008.896 PMid:19109119 DOI: https://doi.org/10.1001/jama.2008.896

Kelly AM, Mathema B, Larson EL. Carbapenem-resistant Enterobacteriaceae in the community: A scoping review. Int J Antimicrob Agents. 2017;50(2):127-34. https://doi.org/10.1016/j.ijantimicag.2017.03.012 PMid:28647532 DOI: https://doi.org/10.1016/j.ijantimicag.2017.03.012

Nasiri MJ, Mirsaeidi M, Mousavi SM, Arshadi M, Fardsanei F, Deihim B, et al. Prevalence and mechanisms of carbapenem resistance in Klebsiella pneumoniae and Escherichia coli: A systematic review and meta-analysis of cross-sectional studies from Iran. Microbial Drug Resist. 2020;26(12):1491-502. https://doi.org/10.1089/mdr.2019.0440 PMid:32348701 DOI: https://doi.org/10.1089/mdr.2019.0440

Kotb S, Lyman M, Ismail G, Abd El Fattah M, Girgis SA, Etman A, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in Egyptian intensive care units using national healthcare-associated infections surveillance data, 2011-2017. Antimicrob Resist Infect Control. 2020;9(1):1-9. https://doi.org/10.1186/s13756-019-0639-7 PMid:31911830 DOI: https://doi.org/10.1186/s13756-019-0639-7

Elshamy AA, Aboshanab KM. A review on bacterial resistance to carbapenems: Epidemiology, detection and treatment options. Future Sci OA. 2020;6(3):FSO438. https://doi.org/10.2144/fsoa-2019-0098 PMid:32140243 DOI: https://doi.org/10.2144/fsoa-2019-0098

Castanheira M, Deshpande LM, Woosley LN, Serio AW, Krause KM, Flamm RK. Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms. J Antimicrob Chemother. 2018;73(12):3346-54. https://doi.org/10.1093/jac/dky344 PMid:30219857 DOI: https://doi.org/10.1093/jac/dky344

Walkty A, Karlowsky JA, Baxter MR, Adam HJ, Zhanel GG. In vitro activity of plazomicin against gram-negative and gram-positive bacterial pathogens isolated from patients in Canadian hospitals from 2013 to 2017 as part of the CANWARD surveillance study. Antimicrob Agents Chemother. 2019;63(1):e02068-18. https://doi.org/10.1128/AAC.02068-18 PMid:30373806 DOI: https://doi.org/10.1128/AAC.02068-18

US Food. Drug Administration Antimicrobial Drugs Advisory Committee. FDA Briefing Document: Plazomicin Sulfate Injection (NDA 210303). United States: US Food; 2018.

Mok WW, Brynildsen MP. Resistance and tolerance to aminoglycosides. In: Bacterial Resistance to Antibiotics-From Molecules to Man. United States: John Wiley and Sons, Inc.; 2019. p. 81-100. DOI: https://doi.org/10.1002/9781119593522.ch4

Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 29th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2019.

Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.

Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011;70(1):119-23. https://doi.org/10.1016/j.diagmicrobio.2010.12.002 PMid:21398074 DOI: https://doi.org/10.1016/j.diagmicrobio.2010.12.002

Andrei S, Droc G, Stefan G. FDA approved antibacterial drugs: 2018-2019. Discoveries. 2019;7(4):e102. https://doi.org/10.15190/d.2019.15 PMid:32309620 DOI: https://doi.org/10.15190/d.2019.15

Tawfick MM, Alshareef WA, Bendary HA, Elmahalawy H, Abdulall AK. The emergence of carbapenemase bla NDM genotype among carbapenem-resistant Enterobacteriaceae isolates from Egyptian cancer patients. Eur J Clin Microbiol Infect Dis. 2020;39(7):1251-9. https://doi.org/10.1007/s10096-020-03839-2 PMid:32062725 DOI: https://doi.org/10.1007/s10096-020-03839-2

Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasević AT, et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): A prospective, multinational study. Lancet Infect Dis. 2017;17(2):153-63. https://doi.org/10.1016/S1473-3099(16)30257-2 PMid:27866944 DOI: https://doi.org/10.1016/S1473-3099(16)30257-2

Raheel A, Azab H, Hessam W, Abbadi S, Ezzat A. Detection of carbapenemase enzymes and genes among carbapenem-resistant Enterobacteriaceae isolates in Suez Canal university hospitals in Ismailia, Egypt. Microbes Infect Dis. 2020;1(1):24-33. DOI: https://doi.org/10.21608/mid.2020.25702.1007

Gelmez GA, Can B, Hasdemir U, Soyletir G. Evaluation of phenotypic tests for detection of carbapenemases: New modifications with new interpretation. J Infect Chemother. 2021;27(2):226-31. https://doi.org/10.1016/j.jiac.2020.09.021 PMid:33008736 DOI: https://doi.org/10.1016/j.jiac.2020.09.021

Ghaith DM, Zafer MM, Said HM, Elanwary S, Elsaban S, Al-Agamy MH, et al. Genetic diversity of carbapenem-resistant Klebsiella Pneumoniae causing neonatal sepsis in intensive care unit, Cairo, Egypt. Eur J Clin Microbiol Infect Dis. 2020;39(3):583-91. https://doi.org/10.1007/s10096-019-03761-2 PMid:31773363 DOI: https://doi.org/10.1007/s10096-019-03761-2

Fleischmann WA, Greenwood-Quaintance KE, Patel R. In vitro activity of plazomicin compared to amikacin, gentamicin, and tobramycin against multidrug-resistant aerobic Gram-Negative Bacilli. Antimicrob Agents Chemother. 2020;64(2):e01711-19. https://doi.org/10.1128/AAC.01711-19 PMid:31712206 DOI: https://doi.org/10.1128/AAC.01711-19

Castanheira M, Davis AP, Mendes RE, Serio AW, Krause KM, Flamm RK. In vitro activity of plazomicin against Gram-negative and Gram-positive isolates collected from US hospitals and comparative activities of aminoglycosides against carbapenem-resistant Enterobacteriaceae and isolates carrying carbapenemase genes. Antimicrob Agents Chemother. 2018;62(8):e00313-8. https://doi.org/10.1128/AAC.00313-18 PMid:29866862 DOI: https://doi.org/10.1128/AAC.00313-18

Clark JA, Kulengowski B, Burgess DS. In vitro activity of plazomicin compared to other clinically relevant aminoglycosides in carbapenem-resistant Enterobacteriaceae. Diagn Microbiol Infect Dis. 2020;98(2):115117. https://doi.org/10.1016/j.diagmicrobio.2020.115117 PMid:32755805 DOI: https://doi.org/10.1016/j.diagmicrobio.2020.115117

Jacobs MR, Good CE, Hujer AM, Abdelhamed AM, Rhoads DD, Hujer KM, et al. ARGONAUT II study of the in vitro activity of plazomicin against carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020;64(5):e00012-20. https://doi.org/10.1128/AAC.00012-20 PMid:32152078 DOI: https://doi.org/10.1128/AAC.00012-20

Eljaaly K, Alharbi A, Alshehri S, Ortwine JK, Pogue JM. Plazomicin: A novel aminoglycoside for the treatment of resistant Gram-negative bacterial infections. Drugs. 2019;79(3):243-69. https://doi.org/10.1007/s40265-019-1054-3 PMid:30723876 DOI: https://doi.org/10.1007/s40265-019-1054-3

Zhang Y, Kashikar A, Bush K. In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE). J Antimicrob Chemother. 2017;72(10):2792-5. https://doi.org/10.1093/jac/dkx261 PMid:29091224 DOI: https://doi.org/10.1093/jac/dkx261